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EXECUTIVE SUMMARY
Based on the five-year field experience of using the 1996 WHO protocol for the
assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum
malaria in areas with intense transmission, many experts have suggested the need to
modify and up-date the protocol. Several teams in Africa have already introduced
modifications. In response to the rapid spread of drug resistance and the slow rate at
which new antimalarial drugs are developed, it is recommended that treatment policy
should focus on therapy with antimalarial drug combinations. The implementation of
combination therapy will likely require modification of the design of the therapeutic
efficacy test. Furthermore, the WHO protocol for monitoring resistance of Plasmodium
falciparum in low to moderate transmission areas and the P. vivax protocol are still in
the draft stages.
It was therefore considered timely to convene a consultation on monitoring anti-
malarial drug resistance. The consultation, which was jointly organized by Emerging
Public Health Risks including Drug Resistance, Communicable Disease Surveillance
and Response (CSR/EPH) and Roll Back Malaria (RBM), was held at WHO
headquarters in Geneva from 3 to 5 December 2001.
The objectives of this consultation were:
· to review and update WHO protocols for assessing the therapeutic efficacy of
antimalarial drugs for treatment of uncomplicated falciparum malaria in areas with
intense transmission (WHO/MAL/96.1077) and in areas with low to moderate
transmission;
· to review the draft guidelines for assessing the therapeutic efficacy of chloroquine
for vivax malaria;
· to review the role of in vitro tests and current methods for detecting molecular
markers in the surveillance of resistance to antimalarial drugs;
· to define the technical and operational elements needed for strengthening surveil-
lance of drug resistance of both falciparum and vivax malaria at the country level.
The consultation was attended by scientists, physicians, researchers, epidemiologists
and statisticians from Africa, the Americas, Asia and Europe (Annex 1). It included
presentations based on working papers, plenary sessions and group discussions on
three main topics: P. falciparum therapeutic efficacy test methods, P. vivax therapeutic
efficacy test methods, and in vitro tests and molecular markers.
This report gives details of the various modifications and complementary information
to be included, which was agreed by experts during the consultation. All these
modifications will be taken into account in the new WHO protocol for monitoring the
efficacy of antimalarial drugs for the treatment of P. falciparum and P. vivax.
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The following are the main recommendations:
· The classification of therapeutic response should be modified in order to obtain
a similar classification for both intense and low to moderate transmission areas.
· The analytical and statistical procedures should be revised.
· The quality assurance process to be used during the monitoring should be
increased and better defined.
· The role and the choice of the sentinel site system should be clearly specified.
· The draft protocol for P. vivax should be simplified.
· Operational research for the development of new tools should be strengthened and
the existing in vitro tests and molecular markers standardized.
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1. BACKGROUND
1.1 Monitoring Plasmodium falciparum  resistance to antimalarial drugs
The first standardized test systems for the assessment of in vivo drug response in
P. falciparum were developed in 1965 shortly after the first reports of chloroquine
resistance in this species. These test systems were subsequently revised in 1967 and
remained largely unchanged until the WHO Scientific Group on the Chemotherapy
of Malaria and Resistance to Antimalarials in 1972 modified them to their present
form. The standardized tests were originally developed for chloroquine. In their
performance, these tests follow set criteria for the administration of a standard
treatment regimen of the appropriate drug, and daily parasitological blood examination
for the stipulated period, i.e. 7 or 28 days for chloroquine. The performance of these
tests in the field was constrained by the need for daily blood examination in the first
week followed by twice-weekly blood examination, when follow-up was extended
beyond 7 days. In addition, these tests were primarily conceived for the assessment
of the parasitological response of P. falciparum in areas with low to moderate malaria
transmission and took practically no note of the clinical response to the drugs and the
immunity of the patient. Because of the lack of clinical information, which would in
many situations be necessary to inform policy-makers, it was decided to introduce a
simplified test system where the number of parasitological observations was reduced
and complemented by standardized clinical observations.
A standardized protocol has been developed by the Centers for Diseases Control and
Prevention, Atlanta (United States) and WHO to assess the therapeutic efficacy of
antimalarial drugs against clinically manifest infections with P. falciparum in infants
and young children in areas of intense transmission. In the preparation of this protocol,
due note has been taken of earlier work towards the same objective, as reflected in
WHO document WHO/MAL/94.1070, Antimalarial Drug Policies. An advanced
version of the protocol was reviewed and endorsed in August 1996, at the inter-
country workshop on “Malaria Treatment and Resistance in Kenya, Zambia and
Malawi” (Mangochi, Malawi). It is presented as the current WHO standard method
for monitoring the therapeutic efficacy of antimalarial drugs for the treatment of
children suffering from uncomplicated falciparum malaria in areas of intense
transmission (WHO document WHO/MAL/96.1077, Assessment of therapeutic
efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with
intense transmission). However, it is obvious that there are large areas in the South-
East Asia, Western Pacific and East Mediterranean Regions, South and Central
America, as well as in tropical Africa, where malaria transmission is of low intensity
or shows large cyclical variations verging on epidemics. In these areas, the level
of immunity is generally low. As these areas are also affected by drug resistant
P. falciparum and the clinical consequences of resistance are even more marked than
in areas with stable malaria, the protocol still required adaptation for areas with
moderate or low endemicity.
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Therefore, a protocol was presented and reviewed at the “Interregional Meeting on
Malaria Control with Emphasis on Drug Resistance”, Manila, Philippines, October
1996, and at the expert meeting in Manaus Brazil, March 1998 (OPS/HCP/HCT/
113/98, Evaluación de la eficacia terapeutica de los medicamentos para el trata-
miento del paludismo por Plasmodium falciparum sin complicaciones en las
Americas). During the “Informal Consultation on Monitoring Drug Resistance to
Antimalarial Drugs in the Mekong Region”, Phnom Penh, October 2000, several
modifications were suggested and included in a draft protocol (March 2001) for
adaptation to areas with low to moderate transmission rates, highlighting in particular
the need for a comprehensible classification suitable both in areas of intense
transmission and those with low to moderate transmission.
1.2 Monitoring Plasmodium vivax resistance to chloroquine
Resistance to chloroquine by P. vivax was first confirmed among Australians
repatriated from Papua New Guinea. Reports of chloroquine-resistant P. vivax have
since come from several regions in India, Indonesia and Myanmar, as well as from
Brazil and Guatemala. It was also observed in travellers to Guyana (South America)
repatriated to Canada. Other reports have documented uniform susceptibility to
chloroquine in Azerbaijan, the Philippines and Thailand. Health policy decisions
concerning chloroquine used for vivax malaria should be based upon evaluation of
chloroquine-resistant P. vivax epidemiology using a standardized protocol.
The need for a standard procedure for diagnosis of chloroquine-resistant P. vivax was
recognized at a meeting in Manaus, Brazil (March 1998) convened by the Pan
American Health Authority (PAHO) to adapt the 1996 WHO protocol for monitoring
the efficacy of antimalarial drugs for the treatment of falciparum malaria to a format
relevant to the American setting. Experts from the American Region attending this
meeting expressed their concern that therapeutic failure of P. vivax infections was
already perceived as a problem of significant impact on public health, and that there
was no standard protocol for assessing the problem. The PAHO expert group prepared
a draft protocol for the assessment of chloroquine sensitivity of P. vivax in different
parts of the world. As a follow-up to this meeting, meetings were held in São Luis
(Brazil) in February 2000 and in Salvador (Brazil) in March 2001. The objectives
were to discuss the use, viability and suggestions for improvement of the draft
protocol for monitoring the response of P. vivax to chloroquine and to share the results
of studies undertaken in the different regions using the draft P. vivax protocol. The
draft protocol elaborated in Manaus was further modified, resulting in the present
version which was discussed during this consultation.
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2. OBJECTIVES OF THE CONSULTATION
· To review and update WHO protocols for the assessment of the therapeutic
efficacy of antimalarial drugs for the treatment of uncomplicated falciparum
malaria in areas with intense transmission (WHO/MAL/96.1077) and with low to
moderate transmission.
· To review the draft guidelines for the assessment of therapeutic efficacy of
chloroquine in vivax malaria.
· To review the role of in vitro tests and current methods for the detection of
molecular markers in the surveillance of resistance to antimalarial drugs.
· To define the technical and operational issues of strengthening surveillance of
drug resistance of both falciparum and vivax malaria at the country level.
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3. PLASMODIUM FALCIPARUM THERAPEUTIC
EFFICACY TEST METHODS
3.1 Introduction
The principal recommendation from the working group was to revise the current in
vivo protocol in order to:
1. Develop a single, globally standardised protocol that outlines procedures for
monitoring antimalarial drug efficacy against P. falciparum in endemic countries;
2. Recommend specific modifications that might be used to tailor these methods in
accordance with differences in the local epidemiology of malaria, especially
transmission intensity;
3. Modify the current in vivo response classification system to allow for a single
system usable in all endemic areas;
4. Clarify areas of the current protocol that are currently ambiguous;
5. Provide ancillary notes to improve understanding of the test methodology.
The group focused on modifications that were relevant to the primary intent of the
protocol, namely the monitoring of drug efficacy over time for strictly programmatic
purposes. It was recognized that these methods would not, nor should be expected to,
provide all possible scientific information necessary for understanding drug efficacy
and resistance in a given environment. Rather, they are intended to ensure a minimal
evidence base from which ministries of health can develop informed treatment
guidelines and policies.
3.2 Specific recommendations
3.2.1 Inclusion and exclusion criteria
Target age groups.  In all areas, the methods should emphasize treatment efficacy in
young children (age < 5 years) with clinical malaria. The rationale behind this
requirement is that, even in populations with low acquired immunity, younger children
often have a less favourable response to antimalarial drugs than older children and
adults. It was recognized, however, that in areas of low transmission, preferential
enrolment of children < 5 years could pose logistical difficulties (e.g. greatly
extending the period of enrolment). In such cases, or in environments where young
children are at substantially lower risk of infection than adults (such as the
occupational exposure seen in some South-East Asian countries), all ages can be
enrolled. Nonetheless, wherever possible, it is recommended that a sufficient number
of patients be enrolled to allow for stratification of results based on age (< 5 years and
³ 5 years).
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Specific Drug Considerations.  Several drugs have specific exclusion criteria. For
example, atovaquone-proguanil (Malarone®), artemether-lumefantrine (Co-artem®,
Riamet®), and halofantrine have minimum age or weight cut-off points below which
treatment is not recommended.
Exclusion of children < 6 months.  Although this exclusion criterion will be retained,
additional information is urgently needed to define differences regarding use, safety
and efficacy in the very young child (< 6 months).
Fever vs. measured temperature elevation
a) The measurement of fever is not always accurate and the correlation between
axillary, rectal and aural elevations in temperature is unreliable. Nevertheless,
fever, as defined in this protocol, is a useful working definition and excludes
normal diurnal variation as a cause of an elevated temperature reading. Fever is
defined as (i) axillary temperature ³ 37.5 °C , (ii) rectal or tympanic temperature
³ 38 °C. The protocol should specify the method used for measuring temperature.
b) In areas of intense transmission, enrolment of patients should be based on
measured fever (an elevated body temperature indicating fever as per the
definitions above). History of fever alone is not sufficient. This enrolment criterion
does not suggest that parasitemic patients without a manifest fever do not have
malaria requiring treatment. It only suggests that, for the purposes of this assess-
ment, objective measures of fever are required for enrolment. Patients not meeting
this admittedly restrictive definition of malaria still require treatment, albeit outside
the context of the assessment.
c) In areas of intense transmission, determination of outcome should also be based on
manifest, measured elevations in temperature only; history of fever alone will not
be considered a sufficient indicator for determination of treatment failure.
d) In areas of low transmission, it is recommended that manifest fever also be used
as an enrolment criterion. However, it is recognized that application of this
requirement may pose logistical constraints in terms of enrolling sufficient
numbers of patients in a reasonable time period. Therefore, in areas of low
transmission only, where history of fever is deemed reliable, a measured elevation
in temperature or a history of fever can be used as an adequate enrolment criterion.
e) In areas of low transmission, unlike most programmes in areas of intense
transmission, the programmatic response to presence of parasitemia after treatment
does not differ between patients with history of fever or with or without overt
clinical symptoms (i.e. symptomatic and asymptomatic parasitemia are weighted
equally and require rescue treatment as a treatment failure).
f) History of fever is defined as a history of fever within the previous 24 hours
preceding enrolment only.
g) Patients will no longer be excluded on the basis of a measured temperature
³ 39.5 °C, in keeping with the updated definitions of severe malaria in the
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Transactions Supplement (2000) [Severe falciparum malaria. Transactions of the
Royal Society of Tropical Medicine and Hygiene, 94; supplement 1].
Parasitemia. Limits of parasite count for inclusion have been changed from 1 000–
30 000/ml to 1 000–100 000/ml for low transmission area, and from 2 000–100 000/ml
to 2 000–200 000/ml in areas of intense transmission. These changes are supported by
the description of hyperparasitemia in the Transactions Supplement (2000) [Severe
falciparum malaria. Transactions of the Royal Society of Tropical Medicine and
Hygiene, 94; supplement 1, S1/5 and S1/33].
3.2.2 Classification of response to treatment
A modified classification system of response to treatment has been developed (see
Annex 3).
The definition of Early Treatment Failure for both intense and low to moderate areas
should be modified to reflect the absolute requirement of a measured parasitemia on
Day 2. In intense transmission areas, a blood slide at Day 2 is now mandatory and not
only if fever is present. This criterion has been included for ethical purposes.
The definition of Early Treatment Failure for low to moderate areas should be added
to reflect the absolute requirement of a measured increase in temperature on Day 3.
The current wording specifically refers to the axillary temperature; this should be
modified to allow for other methods of temperature determination and should specify
the appropriate cut-off point for each method.
The definition of Late Clinical Failure remains for areas with intense transmission
“Presence of parasitemia on any day from Day 4 to Day 14 and a measured axillary
temperature ³ 37.5 °C, without previously meeting any of the criteria of early
treatment failure” and, for areas of low to moderate transmission, “Presence of
parasitemia on any day from Day 4 to Day 28 and a measured axillary temperature
³ 37.5 °C, without previously meeting any of the criteria of early treatment failure”.
Insertion of a footnote is required for the definition of Late Clinical Failure in areas
of low to moderate transmission. In assessments conducted in areas that have chosen
to accept the addition of history of fever during the preceding 24 hours as an
enrolment criterion, definitions of Late Clinical Failure should also include history
of fever (e.g. “Presence of parasitemia and either measured elevation of temperature
or history of fever during the preceding 24 hours from any day between Day 4 and
Day 28, without previously meeting any of the criteria of early treatment failure.”).
Note. On Day 3 of the study, an important indicator of treatment failure is parasitemia
plus measured elevation in temperature. Because of the frequency of fevers occurring
on Day 2, allowing the use of history of fever on Day 3 will substantially and
incorrectly increase the apparent early failure rate. Therefore, history of fever should
not be used on Day 3 or before.
The definition of Late Parasitologic Failure for areas with intense transmission has
been added: “Presence of parasitemia on Day 14 and a measured axillary temperature
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of less than 37.5 °C, without previously meeting any of the criteria of early treatment
failure or late clinical failure.”
The definition of Late Parasitologic Failure for areas of low to moderate transmission
has been added: “Presence of parasitemia on any day from Day 7 to Day 28 and a
measured axillary temperature of less than 37.5 °C, without previously meeting any
of the criteria of early treatment failure or late clinical failure.”
The protocol should emphasize the need to use sound clinical judgement at all times
to ensure patient safety and for determining the appropriateness of any individual
patient’s continuation in the assessment. This applies especially to patients identified
as parasitemic but afebrile on Day 7 in areas of intense transmission. While the
assessment calls for continued monitoring of these patients for an additional seven
days, patients that are judged to be of particular concern (such as afebrile patients with
high parasitemia) could and should be monitored more carefully, including admission
to hospital for closer observation or reassessment on the following day. At any time,
a patient that is deemed unfit to continue the assessment because of safety concerns
may be withdrawn from the assessment and classified in the failure group.
The protocol should include the updated definition of severe malaria as outlined by
WHO (2000). [Severe falciparum malaria. Transactions of the Royal Society of
Tropical Medicine and Hygiene, 94; supplement 1.]
A more detailed explanation of the difference between “treatment failure”, “with-
drawal”, and “loss to follow-up” is required. For example, movement of a patient from
the study site to a place outside the reach of active follow-up should be classified as
“loss to follow-up” and not withdrawal. In all cases, reasons for withdrawal and loss
to follow-up should be recorded and reported in detail. See also section on analytic
plan below, regarding the analytic handling of withdrawals and patients loss to follow-
up.
3.2.3 Analytic and statistical issues (including sample size calculations)
There should be a statement that the fundamental design of this protocol is intended
to provide essential information for monitoring therapeutic efficacy of a range of
antimalarial drugs against uncomplicated falciparum malaria as needed for program-
matic purposes. Additions to the protocol that do not change its fundamental design
could be made, such as measuring blood levels of the drugs, extending the period of
follow up and testing for molecular markers. Certain other types of therapeutic trials,
however, such as evaluation of new antimalarial drugs or comparative evaluation of
two therapies usually require a different type of design not addressed by this protocol.
The recommendations for appropriate methods for calculating sample size represent
a substantial departure from the most recent WHO protocol. The Lot Quality
Assurance method (LQAS) has been used as a way to minimize the amount of field
work required, but the patients included in the studies should have been chosen
randomly.
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This was rarely the case in the trials carried out since 1996. Also, although LQAS is
used to determine sample size, it is far too often forgotten by the time the analysis is
done (i.e. the study is analysed as if traditional sample size calculations were done and
the interpretation is often incorrect). It has been agreed that LQAS is a valuable option
if used properly and has the advantage of stopping the study after the 16th patient.
Nevertheless, the group recommended the use of classical statistical methods for
determining sample size, based on an expected proportion of treatment failures,
desired confidence level (95%) and precision (5% or 10%). The table on minimal
sample size for a prevalence study in the draft protocol can be simplified by including
only the row corresponding to precision of 0.05 and 0.1. In the case of an expected
failure rate lower than 15% and in order to be representative, a minimum of 50
patients should be included.
The preferred method for analysing data derived from these assessments is the life-table
method. This method allows for inclusion of data from patients that are withdrawn or
loss to follow-up without requiring that assumptions be made about ultimately unknown
outcomes. This provides the essential benefits of intent-to-treat analysis with fewer of
the intent-to-treat method’s drawbacks. Recommendation of this method as the preferred
method, however, has greater implications for explanation and training. Although life-
table analysis can be accomplished by hand, access to computer assistance will greatly
increase ease of analysis and reduce calculation errors.
It is recognized that adoption of the life-table method is a significant change from
previously used methods (almost uniformly, the “per protocol” method), creating
problems with comparing new data with historical data. It might also be necessary or
desirable for preliminary analysis to be conducted by people unfamiliar with or
untrained in life-table methodology (and by people without access to computer
support). Therefore, it is also recommended that a traditional “per protocol” method
be used in parallel (the “per protocol” method removes all unevaluable patients [i.e.
those withdrawn or loss to follow-up] from the denominator). It is highly recom-
mended that results from both types of analyses be reported.
Detailed instructions on how to analyse data by hand using both methods should be
included in the final protocol document. However, computer-based applications will
be developed to provide assistance in all aspects of data management and analysis.
3.2.4 Recommended duration of assessment
Areas of intense transmission. The recommended minimum length of follow-up is 14
days. Studies of longer duration in areas of intense transmission must be accompanied
by molecular assessment (PCR) to assist in distinguishing recrudescence from re-
infection. Several participants emphasized the need for a longer period of follow-up
depending on the drug used. Based on several trials and experiences, it is obvious that
a 14-day follow-up underestimates the true rate of failures. The most suitable duration
of follow-up for chloroquine, amodiaquine, sulfadoxine-pyrimethamine, mefloquine
and artemether-lumefantrine should be 28, 28, 42, 63 and 42 days respectively.
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Areas of low to moderate transmission. The recommended length of follow-up for
assessments conducted in areas of low to moderate transmission is 28 days. However,
in some circumstances, assessments of shorter duration (minimum of 14 days) can still
provide useful results and may be utilized. Molecular assessment to assist in
distinguishing recrudescence from re-infection is recommended, but not strictly
essential, for studies of more than 14 days duration.
3.2.5 Drug regimens not covered by this protocol
This protocol is not designed to assess drug regimens given over periods longer than
3 days, such as quinine for 7 days, combinations of quinine and tetracycline or
doxycycline given over 7 days, or artemisinin derivatives given for 5 to 7 days.
3.2.6 Quality assurance
All aspects of the assessment should be subject to quality assurance procedures.
Recommendations regarding quality assurance of four particularly important aspects
(microscopy, temperatures, data management, drugs) are described below.
Training. Quality assurance begins with proper training and supervision of personnel,
and attention to methods and data. Sufficient time and resources should be allocated
to training prior to initiating the assessment. Many staff can be trained adequately with
minimal time investment and appropriate ongoing supervision. Because the validity
of the assessment and the safety of the patients are dependent upon them, the
competence of key study personnel should be ensured, including microscopists and
principal medical staff.
Haematologic assessment. It is an optional activity. Should it be used by a specific
programme, haematologic status assessment ought to be subject to quality control
procedures appropriate to the specific method used.
Quality control of microscopy
a) Quality control of microscopy involves ensuring that i) quality Giemsa stain is
used, ii) staining procedures adhere to recognized methods, iii) the equipment is
of adequate quality and in good repair, and iv) the microscopic results are reliable.
The current protocol adequately describes the staining procedures, but should be
expanded to better describe the other issues. In particular, methods for assuring the
quality of microscopic results should be provided.
b) It is recommended that microscopic results be assessed with the following
procedure that emphasizes reproducibility in outcome over reproducibility in exact
parasite counts. The rationale for this system is that wide variation in parasite
counts can be found even between two highly experienced microscopists,
especially at higher parasite densities. For the purposes of this assessment, those
discrepant results that lead to a change in outcome classification are emphasized
over discrepant results for individual blood slides that may make no difference in
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assigning an ultimate classification. In an ideal situation, two different qualified
microscopists should read separately all the slides. If this is not feasible, a 10%
random selection of enrolled patients or a minimum of 10 randomly selected
patients (whichever is greater) should be selected for re-checking. The second
microscopist who is blinded to the patient number, day of follow-up, original
results and patient outcome should re-examine all microscope slides from these
patients. The second microscopist should provide results as if reading the slide for
the first time (i.e. determine if negative or positive and if positive, provide a
parasite count using standard procedures). After all slides have been reviewed, the
patient-specific new data should be reassembled by patient and the results should
be used to assign an outcome using the recommended classification system. The
new outcome should be compared to the original outcome and discrepancies noted.
If more than 10% of the sub-sample (i.e. 1 patient for a sub-sample of 10 patients)
have discordant outcomes, then all study results should be reviewed.
Quality control for measured temperatures.  Since outcome classifications are
dependent on measured temperature (especially in areas of high transmission), both
thermometers and temperature-taking technique should be reviewed and their quality
ensured. The quality of technique should be ensured through proper training and
supervision. Additionally, the current protocol already recommends that measured
temperatures of less than 36.0 °C should be repeated. Thermometers should be tested
prior to the assessment in a water bath of known temperature (i.e. the temperature of
the water bath should be measured using a reliable thermometer, preferably of
laboratory quality, before testing the study thermometers). If logistically possible, this
procedure should be repeated during and at the end of the assessment.
Quality control of data management. Data management in this instance refers to all
aspects of data collection, entry, management and analysis. All case report forms
should be reviewed by the study supervisor on a regular basis during the assessment,
preferably daily, for completeness and accuracy. Data should be computerized using
double entry or a random sample of 10% of computerized records should be selected
and compared to hard-copy case report forms for confirmation of consistency.
Drug quality. Not all drugs of public health importance are produced under good
manufacturing practice (GMP). Even pharmaceutical companies following GMP
standards might produce drugs of poor quality. Full analysis of drug quality using
United States pharmacopoeia or British pharmacopoeia standards is prohibitively
expensive and difficult to arrange for many programs. Some drugs of public health
importance do not have established pharmacopoeia standards. To the extent possible,
programs should obtain test drugs from WHO or other internationally recognized
sources of quality drugs. For drugs that cannot be obtained through such sources,
samples of test drugs should be submitted to the WHO collaborating centres or
regional reference laboratories on quality of drugs for analysis.
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3.2.7 Sentinel site surveillance system
Control programmes should establish sentinel site surveillance to monitor antimalarial
drug efficacy. Although no definitive scientific advice can be given regarding the
number of sites needed, experience suggests that between four and eight sites achieve
a balance between representativeness and practicality. Programmes should increase or
decrease this range as needed to account for geographic size, population distribution and
density, differing malaria epidemiology or ecology and other factors deemed important
to the program. When making such decisions, emphasis must be placed on the need for
a “manageable” number of sites to ensure proper monitoring and supervision.
Again, based on experience rather than definitive science, it is recommended that
assessments be conducted not less frequently than once every 24 months. For
comparability, assessments should be conducted during the same time of year. Most
programmes conducting sentinel site surveillance of therapy efficacy find it easiest to
alternate test sites (e.g. four sites tested per year with each site being assessed every
other year).
Monitoring of therapeutic efficacy should be carried out through a system of well-
selected sentinel sites in order to obtain consistent longitudinal data and to document
trends. At the initial stage, a national core group of experts (national malaria control
programme, ministry of health, universities, institutes of research, national reference
laboratory) should be established to coordinate all the activities, i.e. training,
supervision, collection and analysis of data, and to forward recommendations to the
drug policy-makers. This core group should ensure a good quality of laboratory
diagnostic skill in the sentinel sites and provide continuous logistic support.
The minimal requirements to establishing a sentinel site are the availability of trained
and motivated clinical personnel and microscopists, with a laboratory for blood film
examination. This can be at the periphery (community-based), or based at a health
facility at district level. Hospitals in urban settings may have more complex clinical
presentations, be more likely to have been referred because of previous drug failures
and may be more difficult to follow up. Whenever possible the monitoring should be
done at the periphery.
The following characteristics should be considered in the selection of sentinel sites:
· population density;
· accessibility to and feasibility of supervision;
· epidemiology of malaria, especially intensity and seasonality of transmission;
· population mobility and migration (especially in border areas);
· distribution of malaria treatment failures reported by health information system.
The sentinel sites should be selected to be representative of each major epidemio-
logical strata into which the country can be divided.
Monitoring can be carried out either by local personnel at the sentinel site or by a
more specialized mobile team. The choice will vary with the country’s situation
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depending mainly on national resources and availability of trained staff at selected
sentinel sites.
Due to the importance of the private sector in drug procurement and distribution in
many countries, and the heterogeneity of drug resistance, drug utilization and drug
quality studies should be conducted, whenever feasible, in the areas selected for
sentinel site monitoring.
It is likely that results between sites will not be uniform: some sites may identify a
substantial deterioration in treatment efficacy while other sites continue to record an
acceptable response to the same drug. The programme should consider how to respond
to this eventuality: can specific treatment guidelines be targeted to affected areas
without changing national policy or guidelines? How many sites need to show
unacceptable treatment failures before national policy or treatment guidelines are
altered? Once a site demonstrates a high level of treatment failure with the existing
first-line drug and national policy or treatment guidelines are not altered, is there a
need to continue to evaluate that drug or site relationship in the future? At what level
of treatment failure would this occur?
3.2.8 Transmission intensity (see unresolved issues)
Recommendations of methods to use for estimating the intensity of transmission in
areas where this is not already known or otherwise in question should be provided. In
all cases, these methods produce a general guideline for applying this assessment in
characterizing sentinel sites. They are not intended to be used for official risk
stratification and should not be considered as definitive. In the absence of a reliable
surveillance system which could provide data on the actual incidence of malaria in the
sentinel sites, potential methods include:
· Rapid community surveys based on spleen rate, parasite prevalence among
children under 1 year, parasite prevalence distribution or prevalence of true
clinical cases across all age groups.
· Review of existing hospital or health information system data to characterize
pattern of outpatient department attendance, severe morbidity attributed to malaria
or malaria-attributed mortality rates.
· Existing entomological data.
3.2.9 Unresolved issues
It was recognized that further consultations will be required to provide recommenda-
tions regarding the following issues:
Early stopping rule.  Would it be possible to devise a system of interim analysis that
would allow for halting the assessment before the entire sample size has completed
the entire follow-up period if failure rates are above a certain level? With LQAS
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method, the study could be stopped if the observed number of treatment failures is
greater than 5 among the 16 first randomized patients (6/16 = 37.5%).
Overall study validity.  At what level of loss to follow-up should the study be
considered invalid? Should this level differ depending on the duration of follow-up
(realizing that loss to follow-up is greater for longer duration studies)? The number
of losses has been arbitrarily limited to < 10% for a 14-day follow-up period in the
former protocol.
Transmission intensity.  Additional information needs to be gathered in order to better
guide users in assessing malaria transmission intensity. The group discussed offering
a range of options, perhaps prioritized. In any case, sufficient detail on methods to be
used and appropriate cut-off points (with references) needs to be provided.
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4. PLASMODIUM VIVAX THERAPEUTIC EFFICACY
TEST METHODS
4.1 Introduction
A WHO protocol for the assessment of the therapeutic efficacy of chloroquine for
vivax malaria exists already as a working draft. The objective of the working group
was to critically review the draft protocol and suggest guidelines to monitor P. vivax
sensitivity to chloroquine or chloroquine in combination with other drugs (specifically
primaquine). This was done also with due consideration to the modifications
introduced during the present consultation in the protocol for assessing drug efficacy
in P. falciparum malaria.
4.2 Specific recommendations
4.2.1 Inclusion and exclusion criteria
Compared with the draft protocol the adopted inclusion and exclusion criteria were the
following:
Inclusion criteria
· Patients age > 6 months
· Positive for P. vivax monoinfection with parasite density above 250/µl (the lower
limit was 1 000/µl in the previous protocol)
· History of fever during 48 hours prior to time of recruitment
· Ability and willingness to participate based on information given to parent or
guardian and access to health facility
· Informed consent
· Axillary temperature ³ 39.5 °C is no longer considered as a criterion for exclusion
Exclusion criteria
· Presence of clinical condition requiring hospitalization
· Presence of severe malnutrition
· Pregnancy
· Significant concomitant febrile illness which would interfere with follow-up
· Chronic infectious diseases other than malaria (e.g. tuberculosis)
· G6PD deficient when primaquine is assessed
· Known allergy and/or intolerance to drug(s) being tested
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4.2.2 Classification of response to treatment
The distinction between early and late treatment failure has been abandoned. The
group opted for a single definition of treatment failure, i.e. no distinction between
early and late treatment failure. Subjects presenting a P. falciparum infection after
clearance of P. vivax parasites should be treated accordingly and withdrawn. These
should not be considered as P. vivax treatment failures.
The definition of treatment failure includes the following:
· Clinical deterioration due to P. vivax illness requiring hospitalization in presence
of parasitemia.
· Presence of parasitemia and axillary temperature ³ 37.5 °C any time between
Day 3 and Day 28.
· Presence of parasitemia on any day between Day 7 and Day 28, irrespective of
clinical conditions.
4.2.3 Follow-up procedures
Days 0 1 2 3 7 14 21 28 Other day
Clinical examination
and temperature
X X X X X X X X X
Treatment with chloroquine X X X
Parasitemia X X X X X X X X
Haemoglobin X X
CQ + metabolite blood levels X reappearance
Molecular markers X reappearance
Measurements of chloroquine and desethylchloroquine levels and determination of
molecular markers is optional as only few laboratories will be able to do it. Measurement
of chloroquine blood level may help in distinguishing between recrudescence and re-
infection. Parasitemia in presence of chloroquine and desethylchloroquine blood levels
at 100 ng/ml or more is considered as treatment failure. However, the rationale behind
this threshold has been questioned and needs to be validated.
4.2.4 Analytic and statistical issues (including sample size calculations)
(see P. falciparum group)
4.2.5 Quality assurance (see P. falciparum group)
4.2.6 Sentinel site surveillance system (see P. falciparum group)
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4.2.7 Guidance on use of data
The trial profile should be presented in a standard format. Results of the tests should
be presented to policy-makers in verbal as well as written form. Data should be used
by national authority and for subsequent regional and international comparison.
Exchange of information among countries in the same geographic region should be
promoted.
4.2.8 Possible rescue treatments
There is no standard alternative therapy established for P. vivax treatment failure. The
working group proposed re-treatment with chloroquine, as breakthrough parasitemia
could be due to problems of absorption, relapse, new infection, or to residual low
levels of chloroquine. However, during the plenary session this has been challenged.
Many countries have this policy although it is not ideal. It was agreed that in these
cases re-treatment with chloroquine combined with primaquine as from Day 0 would
be a better solution. In these cases the problem of G6PD deficiency should be taken
into account and tested. Quinine can be administered according to local conditions.
Amodiaquine is a possible rescue treatment, although there is little information on its
efficacy against P. vivax.
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5. IN VITRO TESTS AND MOLECULAR MARKERS
Therapeutic efficacy test results remain the basis for antimalarial drug policy decision.
However, tools such as in vitro tests or molecular markers can help to clarify or
complete the overall picture. The objectives of the working group were to update
methods based on accumulated experience and recent advances in understanding drug
action and resistance and to provide information regarding the use or potential use of
supporting technologies such as in vitro and molecular methods.
5.1 In vitro tests
5.1.1 Introduction
Considering their technical difficulties and their cost, in vitro tests should be carried
out only by centres with adequate resources and expertise. In vitro tests can be used:
1. to assess patterns of cross-resistance between different drugs;
2. to assess the baseline susceptibility to drugs to be introduced;
3. to temporally and geographically monitor parasite susceptibility to drugs.
Patterns of cross-resistance.  The patterns of cross-resistance may vary between
different regions and occur mainly among drugs of the same chemical family
(quinine–mefloquine), but also among drugs belonging to different chemical families
(mefloquine–artemisinin). These data can be important when changing the first-line
drug, when deciding on second-line treatment and on rescue treatment during
therapeutic efficacy tests or when combining two or more different drugs.
Assessment of baseline susceptibility to drugs to be introduced. Ideally, in vitro test
results should be available before introducing a new treatment (monotherapy or
combination therapy). Such tests should be performed on an adequate sample size
(between 50 and 100 per sentinel site) and cover all sentinel sites in a given country.
In case in vitro test results are indeterminate, their correct interpretation may require
the genetic analysis of the isolates in order to identify molecular markers for
resistance.
Temporal and geographical monitoring of parasite susceptibility. In vitro tests may
provide an early warning of impending resistance before it becomes clinically
apparent and may help to target therapeutic efficacy studies. In vitro tests can also be
useful in monitoring changes in susceptibility to a drug that has been withdrawn. In
situations where a drug combination is used and where it is not possible to carry out
therapeutic efficacy tests for each component of the combination, in vitro tests can
monitor susceptibility to each drug of the combination.
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5.1.2 Recommendations
In vitro testing can be used for the surveillance of drug resistance at country or
regional level and should not be used for individual diagnosis. A link between malaria
control and research programmes should be established to facilitate such a system. It
is recommended that in vitro tests should be carried out by central reference
laboratories located in endemic countries. There is the need for standardizing the
methodology, especially the cultivation procedures and the reporting of results.
Threshold levels defining resistance must be validated by clinical trials in non-immune
patients specifically for each type of in vitro test. A quality control system should be
set up and should include reference clones.
5.2 Drug resistance molecular markers
Molecular markers have the potential for predicting therapeutic efficacy on a broad
scale and models for their implementation have already been proposed. The collection,
storage and transport of samples for molecular analysis are much easier than for the
in vitro tests and this is a major advantage. However, molecular markers of resistance
are available for only a few drugs and thus far only valid for P. falciparum
(sulfadoxine, pyrimethamine, cycloguanil and chloroquine), while for other drugs they
are not yet determined. This is why the working group recommends the collection of
anonymous blood samples on filter paper from patients participating in the therapeutic
efficacy tests. The analysis of these samples may help in validating new molecular
markers for other drugs. Ethical issues of collecting blood samples for future use was
considered by the working group. The group felt that these issues could be dealt with
by unlinking blood samples to patient identifiers and then conducting anonymous
testing. Regardless, the collection of blood samples for future molecular analysis
should be mentioned and well explained during the informed consent process.
Molecular analysis of blood samples should be carried out in centres with adequate
resources and expertise. Several studies have already been carried out and results
published. Such centres already exist in endemic countries and need more support in
terms of training and resources. Data sharing and method standardization among groups
should be promoted and possibly a global network set up.
In a way similar to in vitro tests, molecular studies of resistance markers could also
provide an early warning system or can target therapeutic efficacy studies. They can
also be useful in monitoring the prevalence of molecular markers in places where a
drug has been withdrawn or where a drug combination is in use.
The models for implementing molecular surveillance require validation in different
epidemiological settings. To date, such a system has been evaluated only in Mali.
Such a system would require close collaboration between malaria control programmes
and research groups involved in the molecular analysis. The final aim would be to
investigate how to use markers to help inform policy decisions by improving the
understanding of how the presence of specific markers relates to clinical outcomes.
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5.3 Operational research
The working group has identified several research subjects that are considered as
priorities.
5.3.1 Genotyping of P. falciparum.
Presently, MSP1, MSP2 and GLURP are well established as genotyping markers for
distinguishing between re-infection and recrudescence in treatment failures. There is
a need to standardize the definition of recrudescence and re-infection based on
molecular analysis. Considering the possible complexity of the parasite population in
a single individual, it is proposed to investigate the usefulness of analysing blood
samples collected at Day 0 and at Day 1. This would require a modification of the
follow-up schedule. Other research subjects identified as important are the assessment
of mixed species infection on the clinical and parasitological outcome of the test and
the relationship between presence of molecular markers of resistance and anaemia.
5.3.2 Other important research issues
· The impact of resistance on anaemia, childhood mortality, gametocyte rate and
malaria transmission.
· Identification of early parasitological and clinical indicators suitable for predicting
treatment failure and the relationship between specific drug pharmacokinetic and
pharmacodynamics and therapeutic outcome.
· Rapid tests to detect counterfeit drugs at peripheral level (a test for chloroquine,
sulfadoxine-pyrimethamine and artesunate exists already).
· Rapid and less expensive methods for detecting G6PD deficiency.
· Simpler and less expensive methods to estimate haemoglobin levels.
· More specific rapid tests to detect significant levels of drugs in blood and urine.
· In vitro tests and genetic markers for resistance to chloroquine and pyrimethamine
for P. vivax.
· Drug efficacy in pregnant women and HIV-positive individuals.
· Assessment of available drugs for alternative treatment of P. vivax chloroquine
failures.
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haemoglobin, adaptation according to transmission area or drugs) P. Bloland
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11: 00 Discussion on WHO efficacy protocols
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16.50  Statistical methods in therapeutic efficacy test
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Annex 3. Classification of response to treatment
I N T E N S E  T R A N S M I S S I O N  A R E A L O W  T O  M O D E R A T E  T R A N S M I S S I O N  A R E A
ETF
• Development of danger signs or severe malaria on Day 1, Day 2 or Day 3, in the presence
of parasitemia
• Parasitaemia on Day 2 higher than Day 0 count irrespective of axillary temperature
• Parasitemia on Day 3 with axillary temperature ³ 37.5 °C
• Parasitemia on Day 3 ³ 25 % of count on Day 0
Late Clinical Failure
• Development of danger signs or severe malaria after Day 3 in the presence of parasitemia,
without previously meeting any of the criteria of early treatment failure
• Presence of parasitemia and axillary temperature ³ 37.5°C on any day from Day 4
to Day 14, without previously meeting any of the criteria of early treatment failure
Late Clinical Failure
• Development of danger signs or severe malaria after Day 3 in the presence of parasitemia,
without previously meeting any of the criteria of early treatment failure
• Presence of parasitemia and axillary temperature ³ 37.5 °C (or history of fever) on any day
from Day 4 to Day 28, without previously meeting any of the criteria of early treatment
failure
Late Parasitological Failure
• Presence of parasitemia on any day from Day 7 to Day 28 and axillary temperature
< 37.5 °C, without previously meeting any of the criteria of early treatment failure or late
clinical failure
Late Parasitological Failure
• Presence of parasitemia on Day 14 and axillary temperature < 37.5°C, without previously
meeting any of the criteria of early treatment failure or late clinical failure
ACPR
• Absence of parasitemia on Day 14 irrespective of axillary temperature without previously
meeting any of the criteria of early treatment failure or late clinical failure or late
parasitological failure.
Early Treatment Failure (ETF)
Late Treatment Failure (LTF)
Adequate Clinical and Parasitological Response (ACPR)
ETF
• Development of danger signs or severe malaria on Day 1, Day 2 or Day 3, in the presence
of parasitemia;
• Parasitaemia on Day 2 higher than Day 0 count irrespective of axillary temperature;
• Parasitemia on Day 3 with axillary temperature ³ 37.5 °C;
• Parasitemia on Day 3 ³ 25 % of count on Day 0.
ACPR
• Absence of parasitemia on Day 28 irrespective of axillary temperature without previously
meeting any of the criteria of early treatment failure or late clinical failure or late
parasitological failure.
